Beta-blocker plus immunotherapy before surgery for stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding a beta-blocker (a blood pressure medicine) to standard immunotherapy before surgery can improve outcomes for people with stomach cancer. It is for patients who also have high blood pressure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with stomach cancer that can be treated with surgery.
- You have high blood pressure that requires treatment.
- You can take beta-blockers (heart or blood pressure medicines) safely.
- You have not had an autoimmune disease or an organ transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of an immunotherapy drug (cadonilimab) with chemotherapy before surgery for stomach cancer. The goal is to see if this approach shrinks tumors more effectively and improves outcomes.
This trial tests a new immunotherapy drug (benmelstobart) given before and after surgery for stomach or gastroesophageal junction cancer. The goal is to see if adding this drug to standard care helps reduce the chance of the cancer coming back.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This study tests combining an immunotherapy drug (PD-1 inhibitor) and a medication to boost your immune system (thymalfasin) with standard chemotherapy and radiation before surgery for stage III cancer where the stomach meets the esophagus. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests whether giving the immunotherapy drug sintilimab along with low-dose radiation before surgery can help shrink stomach cancer that has a specific DNA repair defect (dMMR/MSI-H). The goal is to make surgery more effective and improve outcomes.
This trial tests whether giving a combination of chemotherapy and an immunotherapy drug before surgery helps shrink stomach cancer tumors and improve outcomes. The treatment is given in the neoadjuvant (before surgery) setting for stomach cancer that is locally advanced but not spread.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.